Patents by Inventor J. Gregor Sutcliffe
J. Gregor Sutcliffe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10258623Abstract: The present invention relates to methods and compositions for modulating levels of amyloid-? peptide (A?) exhibited by non-neuronal (i.e., peripheral) cells, fluids, or tissues. The invention also relates to modulation of A? levels via selective modulation (e.g., inhibition) of ?-secretase activity. The invention also relates to methods of preventing, treating or ameliorating the symptoms of a disorder, including but not limited to an A?-related disorder, by administering a compound that results in the modulation of ?-secretase in a non-neuronal tissue, either directly or indirectly to prevent, treat or ameliorate the symptoms of a brain A? disorder, such as Alzheimer's disease.Type: GrantFiled: June 27, 2017Date of Patent: April 16, 2019Assignee: ModGene, LLCInventors: J. Gregor Sutcliffe, Brian S. Hilbush
-
Publication number: 20170360787Abstract: The present invention relates to methods and compositions for modulating levels of amyloid-? peptide (A?) exhibited by non-neuronal (i.e., peripheral) cells, fluids, or tissues. The invention also relates to modulation of AP levels via selective modulation (e.g., inhibition) of ?-secretase activity. The invention also relates to methods of preventing, treating or ameliorating the symptoms of a disorder, including but not limited to an A?-related disorder, by administering a compound that results in the modulation of ?-secretase in a non-neuronal tissue, either directly or indirectly to prevent, treat or ameliorate the symptoms of a brain AP disorder, such as Alzheimer's disease.Type: ApplicationFiled: June 27, 2017Publication date: December 21, 2017Inventors: J. Gregor Sutcliffe, Brian S. Hilbush
-
Patent number: 9707231Abstract: The present invention relates to methods and compositions for modulating levels of amyloid-? peptide (A?) exhibited by non-neuronal (i.e., peripheral) cells, fluids, or tissues. The invention also relates to modulation of A? levels via selective modulation (e.g., inhibition) of ?-secretase activity. The invention also relates to methods of preventing, treating or ameliorating the symptoms of a disorder, including but not limited to an A?-related disorder, by administering a compound that results in the modulation of ?-secretase in a non-neuronal tissue, either directly or indirectly to prevent, treat or ameliorate the symptoms of a brain A? disorder, such as Alzheimer's disease.Type: GrantFiled: November 1, 2012Date of Patent: July 18, 2017Assignee: Modgene, LLCInventors: J. Gregor Sutcliffe, Brian S. Hilbush
-
Publication number: 20160287587Abstract: The present invention relates to methods and compositions for modulating levels of amyloid-? peptide (A?) exhibited by non-neuronal (i.e., peripheral) cells, fluids, or tissues. The invention also relates to modulation of A? levels via selective modulation (e.g., inhibition) of ?-secretase activity. The invention also relates to methods of preventing, treating or ameliorating the symptoms of a disorder, including but not limited to an A?-related disorder, by administering a compound that result in the modulation of ?-secretase in a non-neuronal tissue, either directly or indirectly to prevent, treat or ameliorate the symptoms of a brain A? disorder, such as Alzheimer's disease.Type: ApplicationFiled: November 4, 2015Publication date: October 6, 2016Inventors: J. Gregor Sutcliffe, Floyd E. Bloom, Brian S. Hilbush
-
Publication number: 20140323496Abstract: The present invention relates to methods and compositions for modulating levels of amyloid-? peptide (A?) exhibited by non-neuronal (i.e., peripheral) cells, fluids, or tissues. The invention also relates to modulation of A? levels via selective modulation (e.g., inhibition) of ?-secretase activity. The invention also relates to methods of preventing, treating or ameliorating the symptoms of a disorder, including but not limited to an A?-related disorder, by administering a compound that results in the modulation of ?-secretase in a non-neuronal tissue, either directly or indirectly to prevent, treat or ameliorate the symptoms of a brain A? disorder, such as Alzheimer's disease.Type: ApplicationFiled: November 1, 2012Publication date: October 30, 2014Applicant: Modgene, LLCInventors: J. Gregor Sutcliffe, Brian S. Hilbush
-
Publication number: 20100150944Abstract: The present invention relates to identification of cellular components, genotypes and gene expression profiles associated with mood disorders. In some embodiments, the present invention relates to the correlation between ribosomal protein S6 (RPS6) and depression and/or anxiety. Embodiments of the present invention further relate to regulation of the activity of RPS6, e.g., by p90 Ribosomal S6 protein kinase. Embodiments of the present invention provide methods and compositions for, e.g., diagnosing, treating, and monitoring depression and/or anxiety, or risk thereof, and for selecting, monitoring, and tailoring treatments for depression and/or anxiety.Type: ApplicationFiled: April 15, 2008Publication date: June 17, 2010Applicant: MODGENE, LLCInventors: Brian S. Hilbush, Peter B. Hedlund, Floyd E. Bloom, J. Gregor Sutcliffe
-
Publication number: 20100120787Abstract: The present invention relates to methods and compositions for modulating levels of amyloid-? peptide (A?) exhibited by non-neuronal (i.e., peripheral) cells, fluids, or tissues. The invention also relates to modulation of A? levels via selective modulation (e.g., inhibition) of ?-secretase activity. The invention also relates to methods of preventing, treating or ameliorating the symptoms of a disorder, including but not limited to an A?-related disorder, by administering a compound that result in the modulation of ?-secretase in a non-neuronal tissue, either directly or indirectly to prevent, treat or ameliorate the symptoms of a brain A? disorder, such as Alzheimer's disease.Type: ApplicationFiled: November 13, 2009Publication date: May 13, 2010Applicant: MODGENE, LLCInventors: J. Gregor Sutcliffe, Floyd E. Bloom, Brian S. Hilbush
-
Patent number: 6814967Abstract: The present invention relates generally to nucleic acids encoding a novel neuropeptide designated cortistatin. The cortistatin nucleic acids, proteins and polypeptides thereof along with anti-cortistatin antibodies are useful in both screening methods, diagnostic methods and therapeutic methods related to modulation of sleep and disorders thereof.Type: GrantFiled: January 18, 2001Date of Patent: November 9, 2004Assignee: The Scripps Research InstituteInventors: J. Gregor Sutcliffe, Luis De Lecea, Steven J. Henriksen, George R. Siggins
-
Publication number: 20030215817Abstract: Polynucleotides, polypeptides, kits and methods are provided related to genes regulated by the formation of fatty atherosclerotic lesions, and by administration of a dihydropyridine calcium antagonist, lercanidipine.Type: ApplicationFiled: February 3, 2003Publication date: November 20, 2003Inventors: Amedeo Leonardi, Abraham Sartani, James R. Glass, J. Gregor Sutcliffe, Karl W. Hasel
-
Patent number: 6635479Abstract: Disclosed are hypocretin polynucleotides and hypocretin polypeplides, as well as antibodies, oligonucleotides, diagnostic kits and methods, and therapeutic compositions and methods. Hypocretin, one of several novel liypothalamic-specific polypeptides identified isolated and sequenced, is localized to regions of the hypothalamus involved in appetite and feeding behavior. Hypocretin polypeptides are biologically active, producing electrical changes in neurons, lowering body temperature and reducing food intake.Type: GrantFiled: February 2, 1999Date of Patent: October 21, 2003Assignee: The Scripps Research InstituteInventors: J. Gregor Sutcliffe, Kaare M. Gautvik, Luis De Lecea, Floyd E. Bloom, Patria E. Danielson, Vigdis T. Gautvik, Thomas S. Kilduff, Pamela E. Foye
-
Patent number: 6633818Abstract: An improved method for the simultaneous sequence-specific identification of mRNAs in a mRNA population allows the visualization of nearly every mRNA expressed by a tissue as a distinct band on a gel whose intensity corresponds roughly to the concentration of the mRNA. In general, the method comprises the formation of cDNA using anchor primers to fix a 3′-endpoint, producing cloned inserts from the cDNA in a vector containing a bacteriophage-specific promoter for subsequent RNA synthesis, generating linearized fragments of the cloned inserts, preparing cRNA, transcribing cDNA from the cRNA using a set of 5′-RT primers, and performing PCR using a 3′-PCR primer whose sequence is derived from the vector and a set of 5′-PCR primers that is derived from the 5′-RT primers used for transcription of cDNA from cRNA. The method can identify changes in expression of mRNA associated with the administration of drugs or with physiological or pathological conditions.Type: GrantFiled: August 1, 2000Date of Patent: October 14, 2003Assignee: The Scripps Research InstituteInventors: J. Gregor Sutcliffe, Karl W. Hasel
-
Publication number: 20030176666Abstract: Peptides and polypeptides found in the hypothalamus region of the mammalian brain are described, particularly hypocretin polypeptides and their uses. Hypocretin polypeptides are biologically active and produce electrical changes in neurons, lower body temperature, and reduce food intake.Type: ApplicationFiled: December 12, 2000Publication date: September 18, 2003Applicant: The Scripps Research InstituteInventors: J. Gregor Sutcliffe, Kaare M. Gautvik, Luis De Lecea, Floyd E. Bloom, Patria E. Danielson, Vigdis T. Gautvik, Thomas S. Kilduff, Pamela E. Foye
-
Patent number: 6596484Abstract: An improved method for the simultaneous sequence-specific identification of mRNAs in a mRNA population allows the visualization of nearly every mRNA expressed by a tissue as a distinct band on a gel whose intensity corresponds roughly to the concentration of the mRNA. In general, the method comprises the formation of cDNA using anchor primers to fix a 3′-endpoint, producing cloned inserts from the cDNA in a vector containing a bacteriophage-specific promoter for subsequent RNA synthesis, generating linearized fragments of the cloned inserts, preparing cRNA, transcribing cDNA from the cRNA using a set of primers, and performing PCR using a 3′-primer whose sequence is derived from the vector and a set of 5′-primers that is derived from the primers used for transcription of cDNA from cRNA. The method can identify changes in expression of mRNA associated with the administration of drugs or with physiological or pathological conditions.Type: GrantFiled: August 29, 2000Date of Patent: July 22, 2003Assignee: The Scripps Research InstituteInventors: J. Gregor Sutcliffe, Mark G. Erlander, Karl W. Hasel
-
Publication number: 20030092006Abstract: An improved method for the simultaneous sequence-specific identification of mRNAs in a mRNA population allows the visualization of nearly every mRNA expressed by a tissue as a distinct band on a gel whose intensity corresponds roughly to the concentration of the mRNA. In general, the method comprises the formation of cDNA using anchor primers to fix a 3′-endpoint, producing cloned inserts from the cDNA in a vector containing a bacteriophage-specific promoter for subsequent RNA synthesis, generating linearized fragments of the cloned inserts, preparing cRNA, transcribing cDNA from the cRNA using a set of primers, and performing PCR using a 3′-primer whose sequence is derived from the vector and a set of 5′-primers that is derived from the primers used for transcription of cDNA from cRNA. The method can identify changes in expression of mRNA associated with the administration of drugs or with physiological or pathological conditions.Type: ApplicationFiled: September 25, 2001Publication date: May 15, 2003Applicant: The Scripps Research InstituteInventors: J. Gregor Sutcliffe, Mark G. Erlander
-
Patent number: 6479642Abstract: The present invention relates generally to nucleic acids encoding a novel neuropeptide designated cortistatin. The cortistatin nucleic acids, proteins and polypeptides thereof along with anti-cortistatin antibodies are useful in both screening methods, diagnostic methods and therapeutic methods related to modulation of sleep and disorders thereof.Type: GrantFiled: May 15, 1997Date of Patent: November 12, 2002Assignee: The Scripps Research InstituteInventors: J. Gregor Sutcliffe, Luis De Lecea, Steven J. Henriksen, George R. Siggins
-
Publication number: 20020133000Abstract: The present invention relates generally to nucleic acids encoding a novel neuropeptide designated cortistatin. The cortistatin nucleic acids, proteins and polypeptides thereof along with anti-cortistatin antibodies are useful in both screening methods, diagnostic methods and therapeutic methods related to modulation of sleep and disorders thereof.Type: ApplicationFiled: January 30, 2002Publication date: September 19, 2002Inventors: J. Gregor Sutcliffe, Luis De Lecea, Steven J. Henriksen, George R. Siggins
-
Publication number: 20020127571Abstract: An improved method for the simultaneous sequence-specific identification of mRNAs in a mRNA population allows the visualization of nearly every mRNA expressed by a tissue as a distinct band on a gel whose intensity corresponds roughly to the concentration of the mRNA. In general, the method comprises the formation of cDNA using anchor primers to fix a 3′-endpoint, producing cloned inserts from the cDNA in a vector containing a bacteriophage-specific promoter for subsequent RNA synthesis, generating linearized fragments of the cloned inserts, preparing cRNA, transcribing cDNA from the cRNA using a set of primers, and performing PCR using a 3′-primer whose sequence is derived from the vector and a set of 5′-primers that is derived from the primers used for transcription of cDNA from cRNA. The method can identify changes in expression of mRNA associated with the administration of drugs or with physiological or pathological conditions.Type: ApplicationFiled: September 25, 2001Publication date: September 12, 2002Applicant: The Scripps Research InstituteInventors: J. Gregor Sutcliffe, Mark G. Erlander
-
Publication number: 20020012922Abstract: The invention provides a simplified method for simultaneous sequence-specific identification of multiple mRNA molecules in a mRNA population that eliminates the necessity of making a library in a vector. The invention also provides compositions and data processing systems suitable for the practice of the invention.Type: ApplicationFiled: February 1, 2001Publication date: January 31, 2002Inventors: Brian S. Hilbush, Karl W. Hasel, J. Gregor Sutcliffe, Hwai Wen Chang, Marie Lei A. Callahan, Jeanette Quan
-
Publication number: 20020013456Abstract: The present invention relates generally to nucleic acids encoding a novel neuropeptide designated cortistatin. The cortistatin nucleic acids, proteins and polypeptides thereof along with anti-cortistatin antibodies are useful in both screening methods, diagnostic methods and therapeutic methods related to modulation of sleep and disorders thereof.Type: ApplicationFiled: January 18, 2001Publication date: January 31, 2002Applicant: The Scripps Research InstituteInventors: J. Gregor Sutcliffe, Luis De Lecea, Steven J. Henriksen, George R. Siggins
-
Patent number: 6309834Abstract: An improved method for the simultaneous sequence-specific identification of mRNAs in a mRNA population allows the visualization of nearly every mRNA expressed by a tissue as a distinct band on a gel whose intensity corresponds roughly to the concentration of the mRNA. In general, the method comprises the formation of cDNA using anchor primers to fix a 3′-endpoint, producing cloned inserts from the cDNA in a vector containing a bacteriophage-specific promoter for subsequent RNA synthesis, generating linearized fragments of the cloned inserts, preparing cRNA, transcribing cDNA from the cRNA using a set of primers, and performing PCR using a 3′-primer whose sequence is derived from the vector and a set of 5′-primers that is derived from the primers used for transcription of cDNA from cRNA. The method can identify changes in expression of mRNA associated with the administration of drugs or with physiological or pathological conditions.Type: GrantFiled: May 21, 1999Date of Patent: October 30, 2001Assignee: The Scripps Research InstituteInventors: J. Gregor Sutcliffe, Mark G. Erlander